Results 1 to 10 of about 4,422 (206)

Patient and Provider Perspectives on Acceptability, Access, and Adherence to 17-Alpha-Hydroxyprogesterone Caproate for Preterm Birth Prevention [PDF]

Women's Health Reports, 2021
Background: Preterm birth (PTB) is a pressing maternal and child health issue with long-standing racial inequities in outcomes and care provision. 17-Alpha-hydroxyprogesterone caproate (17OHPC) has been one of few clinical interventions for recurrent PTB
Stephanie M. Garcia, Katherine S. Kellom, Rupsa C. Boelig, Xi Wang, Meredith Matone   +4 more
doaj   +2 more sources

17-alpha hydroxyprogesterone caproate for the prevention of recurrent preterm birth among singleton pregnant women with a prior history of preterm birth: a systematic review and meta-analysis of six randomized controlled trials [PDF]

Obstetrics & Gynecology Science, 2021
To perform a systematic review and meta-analysis of all randomized controlled trials (RCTs) that investigated the clinical benefits of 17-alpha hydroxyprogesterone caproate (17OHPC) in the prevention of recurrent preterm birth (PTB) among singleton ...
Saeed Baradwan, Sahar Hassan Abdulghani, Mohammed Abuzaid, Khalid Khadawardi, Majed Saeed Alshahrani, Abdulrahman Al-Matary, May A. AlRasheed, Najlaa Talat Miski, Aroob Abdulhalim, Yousra Mansour Alturki, Ahmed Abu-Zaid   +10 more
doaj   +2 more sources

17-Alpha-Hydroxyprogesterone vs. Placebo for Preventing of Recurrent Preterm Birth: A Systematic Review and Meta-Analysis of Randomized Trials [PDF]

Frontiers in Medicine, 2021
Background: Preterm birth (PTB) is a leading cause of neonatal morbidity and mortality.Objective: To estimate the effect of 17-alpha-hydroxyprogesterone caproate (17-OHPC) compared to placebo in singleton gestations for reducing the risk of recurrent PTB
Abdulaali R. Almutairi, Hadir I. Aljohani, Nouf S. Al-fadel   +2 more
doaj   +2 more sources

Effectiveness of 17-Alpha-Hydroxyprogesterone in the Prevention of Preterm Labour [PDF]

Pakistan Armed Forces Medical Journal, 2023
Objective: To compare the effectiveness of 17-Alpha- Hydroxyprogesterone in preventing preterm labour. Study Design: Prospective longitudinal study.
Uzma Urooj, Sumaira Khan, Shakeela Parveen, Sajid Ali Shah   +3 more
doaj   +3 more sources

Smoking, 17 Alpha-Hydroxyprogesterone Caproate, and Preterm Birth. [PDF]

Am J Perinatol, 2016
Objective The objective of this study was to determine if maternal smoking modifies the effectiveness of 17 α-hydroxyprogesterone caproate (17OHP-C). Study Design Secondary analysis of the Maternal-Fetal Medicine Units Network trial of 17OHP-C. The prevalence of preterm birth (PTB) by smoking status and treatment group was compared by chi-squared ...
Heyborne KD, Allshouse AA.
europepmc   +4 more sources

The association among cytochrome P450 3A, progesterone receptor polymorphisms, plasma 17-alpha hydroxyprogesterone caproate concentrations, and spontaneous preterm birth. [PDF]

Am J Obstet Gynecol, 2017
Background Infants born
Bustos ML, Caritis SN, Jablonski KA, Reddy UM, Sorokin Y, Manuck T, Varner MW, Wapner RJ, Iams JD, Carpenter MW, Peaceman AM, Mercer BM, Sciscione A, Rouse DJ, Ramin SM, Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network.   +15 more
europepmc   +3 more sources

Metabolism of 17-alpha-hydroxyprogesterone caproate by human placental mitochondria. [PDF]

Reprod Sci, 2012
Perfusion of 17-alpha-hydroxyprogesterone caproate (17HPC) via the maternal circuit of a dually perfused human placental lobule resulted in the extensive formation of 2 metabolites. On the other hand, human placental microsomes biotransformed 17HPC into 5 monohydroxylated metabolites, which did not correspond to those formed during perfusion.
Fokina VM, Zharikova OL, Hankins GD, Ahmed MS, Nanovskaya TN.   +4 more
europepmc   +4 more sources

Pharmacogenomics of 17-alpha hydroxyprogesterone caproate for recurrent preterm birth prevention. [PDF]

Am J Obstet Gynecol, 2014
We hypothesized that genetic variation affects responsiveness to 17-alpha hydroxyprogesterone caproate (17P) for recurrent preterm birth prevention.Women of European ancestry with ≥1 spontaneous singleton preterm birth at
Manuck TA, Watkins WS, Moore B, Esplin MS, Varner MW, Jackson GM, Yandell M, Jorde L.   +7 more
europepmc   +4 more sources

Relationship between 17-alpha hydroxyprogesterone caproate concentration and spontaneous preterm birth. [PDF]

Am J Obstet Gynecol, 2014
17-alpha hydroxyprogesterone caproate (17-OHPC) 250 mg weekly reduces recurrent spontaneous preterm birth (SPTB) in women with a prior SPTB by 33%. The dose is not based on pharmacological considerations. A therapeutic concentration has not been determined hampering any attempt to optimize treatment.
Caritis SN, Venkataramanan R, Thom E, Harper M, Klebanoff MA, Sorokin Y, Thorp JM, Varner MW, Wapner RJ, Iams JD, Carpenter MW, Grobman WA, Mercer BM, Sciscione A, Rouse DJ, Ramin S, Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network and Obstetric-Fetal Pharmacology Research Units Network.   +16 more
europepmc   +4 more sources

17 alpha-hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm. [PDF]

Am J Obstet Gynecol, 2012
To evaluate whether 17-alpha hydroxyprogesterone caproate (17-OHP) reduces preterm birth (PTB) in nulliparous women with a midtrimester cervical length (CL) less than 30 ...
Grobman WA, Thom EA, Spong CY, Iams JD, Saade GR, Mercer BM, Tita AT, Rouse DJ, Sorokin Y, Wapner RJ, Leveno KJ, Blackwell S, Esplin MS, Tolosa JE, Thorp JM, Caritis SN, Van Dorsten JP, Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units (MFMU) Network.   +17 more
europepmc   +3 more sources